Observational Study
Copyright ©The Author(s) 2022.
World J Gastroenterol. Dec 7, 2022; 28(45): 6380-6396
Published online Dec 7, 2022. doi: 10.3748/wjg.v28.i45.6380
Figure 1
Figure 1 Treatment effectiveness (sustained virologic response rates) according to treatment regimens per protocol analysis. ASV: Asunaprevir; DCV: Daclatasvir; DSV: Dasabuvir; EBR: Elbasvir; GLE: Glecaprevir; GZR: Grazoprevir; LDV: Ledipasvir; OBV: Ombitasvir; PIB: Pibrentasvir; PP: Per protocol; PTV/r: Paritaprevir; RBV: Ribavirin; SOF: Sofosbuvir; SVR: Sustained virologic response; VEL: Velpatasvir; VOX: Voxilaprevir.